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A B S T R A C T
Dermal fibroblasts from an autosomal recessive retinitis pigmentosa (RP) patient, homozygous for the mutation c.769 C>T, p.Arg257Ter, in CERKL (Ceramide
Kinase-Like) gene, and a healthy sibling were derived and reprogrammed by Sendai virus. The generated human induced pluripotent stem cell (hiPSC) lines RP3-
FiPS4F1 and Ctrl3-FiPS4F1, were free of genomically integrated reprogramming genes, showed stable karyotypes, expressed pluripotency markers and could be
differentiated towards the three germ layers in vitro. These hiPSC lines offer a useful resource to study RP pathomechanisms, drug testing and therapeutic
opportunities.
Resource table




Alternative names of st-
em cell lines
RP3-FiPS4F1 (ESi066-A), Ctrl3-FiPS4F1 (ESi067-A)




Type of cell lines iPSC
Origin Human





Multiline rationale Disease and healthy sibling control
Gene modification Yes
Type of modification Hereditary
Associated disease Retinitis pigmentosa
Gene/locus CERKL (NM_201548.4), Chr2:g.182423344 G>A (hg19);
Ex 5. c.[769 C>T] (p.Arg257Ter)
Method of modification N/A
















Ethical approval Ethical approval obtained from Valencian Authority for
Stem Cell Reseach DGIITC/AMA/pe S-0081/18
Resource utility
Retinitis pigmentosa (RP), a group of inherited retinal dystrophies
with a worldwide prevalence of 1:4000, is characterized by photo-
receptor degeneration (first rods and later cones) leading to genetic
blindness (reviewed in Verbakel et al., 2018). We have generated hiPSC
lines from a RP patient homozygous for a nonsense mutation in CERKL
(p.Arg257Ter), an autosomal recessive RP gene (Tuson et al., 2004).
This mutation (also listed as p.Arg283Ter, NM_001030311.2) is the
most prevalent CERKL mutation in the Spanish population (Ávila-
Fernandez et al., 2008). The patient's non-affected sister fibroblasts
were also reprogrammed into hiPSCs as a proper control to minimize
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the contribution of genetic background to disease phenotype. The non-
integrative reprogramming strategy was applied in order to avoid in-
sertional mutations and generate footprint-free hiPSCs that do not
contain detectable vectors or transgenes. The cell lines offer a useful
resource for RP pathomechanism studies and drug screening.
Resource details
Dermal fibroblast primary cell lines were derived from skin biopsies
from a retinitis pigmentosa (RP) patient and his non-affected sister.
Fibroblasts were reprogrammed using Sendai virus expressing human
OCT4, SOX, KLF4, c-MYC reprogramming factors (Cytotune 2.0;
Thermo Fisher). Clonal hiPSC lines from each individual were estab-
lished and further characterized (Table 1 and Table 2). Sanger se-
quencing confirmed that the RP patient's fibroblasts (data not shown)
and hiPSC line, RP3-FiPS4F1, harboured a nonsense truncating muta-
tion in CERKL in homozygosity (Fig. 1A, lower panel), in accordance
with previous genotyping data (Tuson et al., 2004). The hiPSCs derived
from the healthy sibling, Ctrl3-FiPS4F1, showed the WT sequence in the
same region (Fig. 1A, upper panel). Both hiPSC lines showed typical
human embryonic stem cell (hESC) –like colony morphology by phase
contrast microscopy (Fig. 1B) and were positive for alkaline phospha-
tase (AP) (Fig. 1C). The expression of pluripotency markers was de-
monstrated by flow cytometry (SSEA-4 and TRA-1-60) (Fig. 1D), im-
munofluorescence analyses of OCT4, SOX2, NANOG, SSEA-4 and TRA-
1-81 (insets show nuclei staining with DAPI) (Fig. 1E), and RT-PCR for
pluripotency markers (Fig. 1F). DNA fingerprinting was used to confirm
the origin of the hiPSC clones (Available with authors). Sendai virus
was eliminated from the hiPSCs' genome at passage 11 (Supplementary
Fig. S1A). To explore genomic integrity, karyotyping was performed
and showed that hiPSC lines, RP3-FiPS4F1 and Ctrl3-FiPS4F1, were
male and female clones, respectively, and presented normal diploid
karyotypes (Supplementary Fig. S1B). The capacity of hiPSCs to dif-
ferentiate into three germ layers was confirmed by the embryoid body
(EB) assay and expression of ectoderm (TUJ1, PAX6), endoderm (AFP,
FOXA2) and mesoderm (VIMENTIN, α-SMA) assessed in differentiating
EB cultures (Fig. 1G). Mycoplasma was regularly tested throughout the
cell culture and was negative (Supplementary Fig. S1C).
Materials and methods
Reprogramming fibroblasts
The primary fibroblasts derived from the skin biopsies were ex-
panded for four passages in DMEM (10% FBS, 2mM Glutamax,
Penicillin-Streptomycin 1×) at 37°C under 5% CO2, before being re-
programmed by a Sendai virus containing four genes: OCT3/4, SOX2,
KLF4 and c-MYC (Cytotune 2.0, Thermo Fisher) according to manu-
facturer's instructions. hiPSCs were grown on irradiated (45Gy) human
foreskin fibroblasts (ATCC CRL 2429) in hiPSC medium containing
Knockout-DMEM, KSR 20%, Glutamax 2mM, non-essential amino acids
0.1 mM, β-mercaptoethanol 0.23mM, basic FGF 10 ng/ml, penicillin/
streptomycin, at 37 °C/5% CO2. The hiPSCs were adapted to feeder-free
cell culture on plates coated with Matrigel (BD, #354277) using
mTeSR1 medium. Matrigel was diluted in DMEM/F-12 according to the
dilution factor specified on the certificate of analysis and incubated for
1 h/RT at 1ml/well of a 6-well plate. Passages were performed using
Dispase (STEMCELL Technologies, #07913), every 5–7 days at 1:6–1:10
split ratio.
In vitro differentiation assay
In vitro differentiation was performed by EB formation, namely the
hiPSC colonies were lifted manually and cultured in non-adherent
conditions in mTeSR1 medium for 24 h, followed by endoderm medium
(Knockout-DMEM, 10% FBS, 1% Glutamax, NEAA 1%, β-mercap-
toethanol 0.23mM, Penicillin-Streptomycin 1×) for the following
6 days. Thereafter, the EBs were seeded on glass coverslips treated with
Table 1
Summary of lines.
iPSC line names Abbreviation in figures Gender Age Ethnicity Genotype of locus Disease
RP3-FiPS4F1 (ESi066-A) RP Male 62 Caucasian CERKL (NM_201548.4), Chr2:g.182423344 G>A (hg19); Ex 5. c.[769
C>T] (p.Arg257Ter)
Retinitis pigmentosa
Ctrl3-FiPS4F1 (ESi067-A) Healthy Female 52 Caucasian CERKL (NM_201548.4) WT Healthy
Table 2
Characterization and validation.
Classification Test Result Data
Morphology Photography Normal Fig. 1 panel B
Phenotype Qualitative analysis
(Immunocytochemistry)
Positive staining/expression of pluripotency markers: OCT4, NANOG,
SOX2, SSEA-4, TRA-1-81
Fig. 1 panel E






Genotype Karyotype (G-banding) and resolution Healthy: 46XX; RP: 46XY Supplementary fig. S1B
Resolution 450–500
Identity Microsatellite PCR (mPCR) OR N/A N/A
STR analysis 10 STR loci analyzed, all matching Available with authors
Mutation analysis (if
applicable)
Sequencing CERKL (NM_201548.4) ex 5. [c.769 C>T] Fig. 1panel A
Southern Blot OR WGS N/A N/A
Microbiology and virology Mycoplasma Mycoplasma testing by luminescence. Negative. Supplementary fig. S1C
Differentiation potential Embryoid body formation Positive TUJ1 and PAX6 for ectoderm, positive α-SMA, VIMENTIN
mesodermal staining and positive AFP and FOXA2 endodermal staining
Fig. 1panel G
Donor screening (optional) HIV 1+2 Hepatitis B, Hepatitis C N/A N/A
Genotype additional info
(optional)
Blood group genotyping N/A N/A
HLA tissue typing N/A N/A
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0.1% gelatin for 2 h/RT and cultured during 2 weeks in three cell cul-
ture media: ectoderm medium (50% Neurobasal medium, 50% DMEM/
F12, 1% N2 supplement, 0.5% B27 supplement, penicillin-streptomycin
1×), endoderm medium and mesoderm medium (endoderm medium,
0.5 mM ascorbic acid). The coverslips were fixed with 4% PFA for
15min and analyzed by immunofluorescence (Table 3). Confocal
images were taken with a Leica SP8 microscope.
Fig. 1. Characterization of Healthy and RP hiPSC lines. A. DNA sequence electropherograms showing the wild type sequence and the c.257C>T mutation in CERKL
in Healthy (upper panel) and RP (lower panel) hiPSC lines. B. Phase contrast micrographs of Healthy and RP hiPSC colonies cultured in feeder-free conditions. C.
Alkaline phosphatase positive staining. D. Flow cytometry of surface pluripotency markers SSEA-4 and TRA-1-60. E. Immunofluorescence for pluripotency markers
OCT4, SOX2, NANOG, SSEA-4, TRA-1-81. Nuclei were counterstained with DAPI (blue). F. RT-PCR analysis of pluripotency genes in Healthy and RP hiPSC lines. G.
Immunocytochemistry for ectodermal (PAX6, TUJ1), endodermal (AFP, FOXA2) and mesodermal (SMA, VITRONECTIN) markers. Nuclei were counterstained with
DAPI (blue).
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Karyotype analysis
The karyotype was analyzed at passage 13 by G-banding at 400–550
band resolution, 30 metaphases analyzed (Service of Biobanco de
Sistema Sanitario Público, Granada, Spain).
Fingerprinting
Genomic DNA (gDNA) from fibroblasts and hiPSCs was extracted
using QIAamp DNA Blood mini kit (Qiagen) in the presence of RNAse
(Roche). Fingerprinting analyses was performed using Promega kit 10
microsatellite markers (TH01, TPOX, vWA, CSF1PO, D16S539, D7S820,
D13S317, D5S818 y D21S11, Amelogenin) and analyzed on Abi PRISM
3130 using GeneMapper (Thermo Fisher) by Biobanco de Sistema
Sanitario Público, Granada, Spain.
Detection of pluripotency markers and vector elimination by RT-PCR
Total RNA was isolated with the RNeasy Mini Kit (Qiagen, Hilden,
Germany), and treated with DNase I to remove any genomic DNA
contamination. QuantiTect Reverse Transcription Kit (Qiagen) was used
to carry out cDNA synthesis from 1 μg of total RNA according to the
manufacturer's instructions. The expression of pluripotency markers
was analyzed using the primers described in Table 3. Patient's fibro-
blasts were used as negative control. For Sendai virus elimination test,
fibroblasts collected at day 7 after transduction were used as positive
control (C+) for Cytotune 2.0 vector detection by RT-PCR. The PCR
reaction was performed with MyTaq DNA Polymerase (Bioline GmbH,
Luckenwalde, Germany) using Applied Biosystems Veriti Thermal Cy-
cler with following steps: denaturation 94 °C for 15 s, annealing
50–65 °C for 30 s, extension 72 °C for 45 s (x 35 cycles). Glyceraldehyde
3-phosphate dehydrogenase (GAPDH) expression was used as a control
housekeeping gene. Thereafter, PCR products were analyzed on 2%
agarose gels.
Immunocytochemistry
hiPSC colonies cultured in plastic dishes were washed in PBS and
Table 3
Reagent details.
Antibodies used for immunocytochemistry/flow-cytometry
Antibody Dilution Company Cat # and RRID
Pluripotency marker Rabbit anti-NANOG 1:400 Cell Signaling Technology Cat# D73G4 #RRID:AB_10559205
Pluripotency marker Rabbit anti-OCT4 1:400 Cell Signaling Technology Cat# C30A3 #RRID:AB_2167691
Pluripotency marker Rabbit anti-SOX2 1:400 Cell Signaling Technology Cat# D6D9 #RRID:AB_2195767
Pluripotency marker Mouse anti-SSEA4 1:100 BD Pharmigen Cat# 560073 #RRID:AB_1645601
Pluripotency marker Mouse anti TRA-1-81 1:100 Milipore Cat# MAB4381 #RRID:AB_177638
Pluripotency marker Mouse anti human SSEA4-PE 1:800 Stem Cell Technologies Cat# 60062PE.1 #RRID N/A
Isotype control Mouse IgG3 kappa-PE 1:6400 Stem Cell Technologies Cat# 60073PE.1 #RRID N/A
Pluripotency marker Mouse anti human TRA- 1-60 1:400 Stem Cell Technologies, Cat #60064PE.1 #RRID N/A
Isotype control PE Mouse IgM 1:400 BD, Pharmingen Cat# 555584 #RRID:AB_395960
Ectoderm marker Mouse anti-TUJ-1 1:500 Neuromics Cat# MO15013 #RRID:AB_2737114
Ectoderm marker Rabbit anti-PAX6 1:500 Covance Cat# PRB-278P #RRID:AB_291612
Mesoderm marker Mouse anti-SMA 1:300 Sigma Cat #A5228 #RRID:AB_262054
Mesoderm marker Mouse anti-VIMENTIN 1:300 Abcam Cat# ab8978 #RRID:AB_306907
Endoderm marker Mouse anti-AFP 1:20 RD Cat# MAB 1368 #RRID:AB_357658
Endoderm marker Goat anti HNF-3β/FOXA2 1:100 RD Cat# 2400 #RRID:AB_2294104
Secondary antibody Anti-mouse IgG 1:500 Invitrogen Cat# A11001 #RRID: AB_2534069
Secondary antibody Anti-rabbit 1:500 Invitrogen Cat# A11002 #RRID:AB_2534070
Secondary antibody Anti-mouse IgM 1:500 Invitrogen Cat# A21042 #RRID:AB_2535711
Secondary antibody Anti-goat 1:500 Invitrogen Cat# A11055 #RRID:AB_2534102
Primers
Target Forward/Reverse primer (5′–3′)
Genotyping CERKL (583 bp) GAGCAAAACGCTGGTCAGATG/GCTAGTGGGGATGCCAGAAG
Pluripotency marker (RT-PCR) OCT4 (165 bp) AAGCCCTCATTTCACCAGG
CTTGGAAGCTTAGCCAGGTC
Pluripotency marker (RT-PCR) SOX2 (181 bp) TCACATGTCCCAGCACTACC
CCCATTTCCCTCGTTTTTCT
Pluripotency marker (RT-PCR) NANOG (260 bp) CCAAATTCTCCTGCCAGTGAC
CACGTGGTTTCCAAACAAGAAA
Pluripotency marker (RT-PCR) REX1 (300 bp) CAGATCCTAAACAGCTCGCAGAAT
GCGTACGCAAATTAAAGTCCAGA
Pluripotency marker (RT-PCR) GDF3 (631 bp) CTTATGCTACGTAAAGGAGCTGGG
GTGCCAACCCAGGTCCCGGAAGTT
Pluripotency marker(RT-PCR) DPPA4 (408 bp) GGAGCCGCCTGCCCTGGAAAATTC
TTTTTCCTGATATTCTATTCCCAT
House-keeping gene (RT-PCR) GAPDH (463 bp) ATCGTGGAAGGACTCATGACCACA
CCCTGTTGCTGTAGCCAAATTCGT
Sendai virus detection (RT-PCR) SeV (181 bp) GGATCACTAGGTGATATCGAG C*
ACCAGACAAGAGTTTAAGAGATATGTATC*
Sendai virus transgene detection (RT-PCR) KOS (528 bp) ATGCACCGCTACGACGTGAGCGC
ACCTTGACAATCCTGATGTGG
Sendai virus transgene detection (RT-PCR) Klf (410 bp) TTCCTGCATGCCAGAGGAGCCC
AATGTATCGAAGGTGCTCAA*
Sendai virus transgene detection (RT-PCR) c-Myc (532 bp) TAACTGACTAGCAGGCTTGTCG*
TCCACATACAGTCCTGGATGATGATG
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fixed in 4% PFA for 15min at room temperature (RT). Fixed cells were
washed twice in PBS and placed in blocking solution (3% serum, 0.5%
Triton-X100 in PBS) for 1 h at RT. Cells were then incubated overnight
at 4 °C with primary antibodies diluted in blocking solution (Table 3).
The following day, cells were washed three times in PBS and incubated
with an appropriate secondary antibody at RT for 1 h. Thereafter, cells
were stained with DAPI (1:1000) at RT during 5min, washed three
times in PBS and imaged with a Leica DMi 8 microscope coupled with a
DFC/7000GT camera.
Flow cytometry
hiPSCs were dissociated using Accutase (Innovative Cell
Technologies) for 2–4min at RT, centrifuged at 300 rcf for 5min and
100,000 cells resuspended in 200 μl PBS+2% FBS. Anti-human SSEA-4
and anti-human TRA-1-60 antibodies, both PE conjugated, were added
and incubated for 20min at RT. Isotype negative controls were used at
the same final concentration (Table 3). 7-Aminoactinomycin D (7-AAD,
Life Technologies) was used to identify live cells. The cells were ana-
lyzed using a CytoFLEX flow cytometer (Beckman Coulter) and data
was analyzed by CytExpert 2.0 software. FACS gates were defined ac-
cording to isotype controls.
Alkaline phosphatase staining
Alkaline phosphatase staining was carried out using Alkaline
Phosphatase Staining Kit II (Stemgent, MA).
Mycoplasma detection
The presence of mycoplasma was tested regularly measuring en-
zyme activity via luciferase (MycoAlert™ PLUS Mycoplasma Detection
Kit, Lonza). Ratios of Reading B/ Reading A < 1.0 are considered ne-
gative for mycoplasma.
hiPSC nomenclature
The generated hiPSC line was named following Spanish National
Stem Cell Bank recommendations. The lines are registered at https://
hpscreg.eu/ as RP3-FiPS4F1 (ESi066-A) and Ctrl3-FiPS4F1 (ESi067-A).
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.scr.2019.101455.
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